Evommune (NYSE:EVMN – Get Free Report) had its price target reduced by equities research analysts at Needham & Company LLC from $28.00 to $25.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC‘s price objective would indicate a potential upside of 226.84% from the company’s previous close.
A number of other equities analysts have also recently weighed in on EVMN. Raymond James Financial set a $18.00 price target on shares of Evommune in a research report on Wednesday, September 9th. Weiss Ratings cut shares of Evommune from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 11th. HC Wainwright reaffirmed a “neutral” rating on shares of Evommune in a research note on Wednesday, September 9th. Royal Bank Of Canada reduced their target price on Evommune from $29.00 to $21.00 and set an “outperform” rating on the stock in a report on Wednesday, September 9th. Finally, Stifel Nicolaus set a $30.00 target price on Evommune in a report on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $30.50.
View Our Latest Analysis on EVMN
Evommune Stock Down 4.6%
Evommune stock traded down $0.37 during midday trading on Friday, hitting $7.65. 723,350 shares of the stock were exchanged, compared to its average volume of 980,729. The company has a fifty day simple moving average of $7.56 and a two-hundred day simple moving average of $17.11. Evommune has a 52 week low of $4.94 and a 52 week high of $33.20. The stock has a market capitalization of $277.58 million and a PE ratio of -2.01.
Evommune (NYSE:EVMN – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.03). As a group, equities research analysts anticipate that Evommune will post -3.35 EPS for the current fiscal year.
Institutional Investors Weigh In On Evommune
Several institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC acquired a new position in Evommune in the 1st quarter worth $20,615,000. Stempoint Capital LP increased its holdings in Evommune by 184.1% during the 1st quarter. Stempoint Capital LP now owns 193,777 shares of the company’s stock worth $4,385,000 after purchasing an additional 125,581 shares in the last quarter. Perceptive Advisors LLC bought a new position in Evommune during the 1st quarter worth about $10,308,000. Defilade Capital Management L.P. raised its stake in shares of Evommune by 215.0% in the 1st quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company’s stock valued at $15,601,000 after purchasing an additional 463,171 shares during the period. Finally, Eversept Partners LP acquired a new stake in shares of Evommune in the 1st quarter valued at about $1,257,000.
Evommune Company Profile
Evommune is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. Founded in 2020, the company focuses on biological pathways involved in inflammation and aims to develop treatments for conditions with significant unmet medical needs. Its pipeline includes EVO756, an oral investigational medicine designed to block MRGPRX2, a receptor involved in mast-cell activation. The candidate is being studied for inflammatory skin disorders, including chronic spontaneous urticaria and atopic dermatitis.
Further Reading
- Five stocks we like better than Evommune
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Evommune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evommune and related companies with MarketBeat.com's FREE daily email newsletter.
